Johnson & Johnson: Continue to believe in positive benefit-risk profile of COVID-19 vaccine
|“We continue to believe in a positive benefit-risk profile of COVID-19 vaccine,” Johnson & Johnson (J&J) said in response to the statement released after the US Centers for Disease Control and Prevention (CDC) Advisory Committee meeting.
J&J said that it has actively postponed the launch of its vaccine in Europe.
Earlier on, the US CDC extended the halt on the distribution of the vaccine amid a lack of more data to assess the risk.
Market reaction
The risk sentiment remains upbeat despite the J&J covid vaccine concerns, with the S&P 500 futures gaining 0.10% to 4,120, at the time of writing.
The US dollar index wallows in multi-week lows, as the sell-off extends into Asia.
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers.